Pluristem Therapeutics, Inc. (PSTI:NASDAQ) Investor Relations Material

Overview

Pluristem Therapeutics Inc. is a regenerative medicine company focusing on developing placenta-based cell therapy product candidates. The company has reported successful clinical trial data in multiple indications for its patented PLX cell product candidates, and is currently conducting late-stage trials in various indications. The PLX cells are grown using the company's proprietary three-dimensional expansion technology and can be administered to patients without tissue matching. Pluristem has a strong intellectual property position, an in-house GMP-certified manufacturing and research facility, strategic relationships with research institutions, and an experienced management team.

Frequently Asked Questions

What is Pluristem Therapeutics, Inc.'s ticker?

Pluristem Therapeutics, Inc.'s ticker is PSTI

What exchange is Pluristem Therapeutics, Inc. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Pluristem Therapeutics, Inc.'s headquarters?

They are based in Haifa, Israel

How many employees does Pluristem Therapeutics, Inc. have?

There are 51-200 employees working at Pluristem Therapeutics, Inc.

What is Pluristem Therapeutics, Inc.'s website?

It is https://www.pluristem.com/

What type of sector is Pluristem Therapeutics, Inc.?

Pluristem Therapeutics, Inc. is in the Healthcare sector

What type of industry is Pluristem Therapeutics, Inc.?

Pluristem Therapeutics, Inc. is in the Biotechnology industry

Who are Pluristem Therapeutics, Inc.'s peers and competitors?

The following five companies are Pluristem Therapeutics, Inc.'s industry peers:

- Immutep Limited

- Cellectis S.A.

- American Virtual Cloud Technologies, Inc.

- C4X Discovery

- Redx Pharma Plc